Lawrenceville, NJ, United States of America

Ricardo Attar

This inventor holds 26 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 6 EPO patents, primarily in Cancer Therapeutics. Top assignees: Janssen Biotech, Inc., Bristol-Myers Squibb Compnay, Janssen Pharmaceutica Nv. Active years: 2002-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ricardo Attar. Retrieved from https://idiyas.com/inventor/ricardo-attar

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 26 (Patent Applications = 5)

% Patents Active = 92.3

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 6 (Patent Applications = 14)

Average Co-Inventor Count = 7.8

ph-index = 7

Forward Citations = 248(Granted Patents)

Location History:

Spring House, PA (US) (2017 - 2018)
Lawrence Township, PA (US) (2020)
Lawrence Township, NJ (US) (2021)
Lawrenceville, NJ (US) (2002 - 2024)

Company Filing History:

11 out of 436

Janssen Biotech, Inc.

patents

10 out of 3,749

Bristol-Myers Squibb Compnay

patents

4 out of 2,103

Janssen Pharmaceutica Nv

patents

4. 1 out of 3,713

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

5. 1 out of 834,708

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2026

Loading Chart...

Areas of Expertise:

EGFR Binding Molecules

GPRC5D Antibodies

Cancer Treatment

Fibronectin Scaffold

Bispecific Antigen Binding

Mutant CALR Vaccines

CD38 Blocking

Nuclear Hormone Receptor Modulators

Polynucleotides

Insulin Growth Factor

Androgen Receptor

Protein Interaction Detection

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE51085 - ANTI-BCMA ANTIBODIES AND USES THEREOF (2026-10-20),

2. 12767934 - VACCINES BASED ON MUTANT CALR AND JAK2 AND THEIR USES (2026-10-20),

3. 12304939 - EGFR and C-met fibronectin type III domain binding molecules (2025-05-20),

4. 12077592 - GPRC5D chimeric antigen receptors and cells expressing the same (2024-09-03),

5. 12018289 - Vaccines based on mutant CALR and JAK2 and their uses (2024-06-25),

6. 11884722 - Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof (2024-01-30),

7. 11685777 - Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof (2023-06-27),

8. 10954284 - EGFR and c-Met fibronectin type III domain binding molecules (2021-03-23),

9. 10774130 - Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins (2020-09-15),

10. 10662235 - Cysteine engineered fibronectin type III domain binding molecules (2020-05-26),

11. 10562968 - Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof (2020-02-18),

12. 10106620 - Blocking CD38 using anti-CD38 F(ab')2 to protect NK cells (2018-10-23),

13. 10072088 - Anti-BCMA antibodies and uses thereof (2018-09-11),

14. 9902762 - Multivalent fibronectin based scaffold domain proteins (2018-02-27),

15. 9850310 - CD123 binding agents and uses thereof (2017-12-26),

Title: Inventor Spotlight: Ricardo Attar

Introduction

Ricardo Attar is a distinguished inventor based in Lawrenceville, NJ, known for his significant contributions to the field of biomedical innovations. With a remarkable portfolio of 23 patents, Attar's work primarily focuses on the development of cutting-edge treatments for cancer.

Latest Patents

Among his notable inventions are two recent patents that highlight his innovative spirit. The first, titled "GPRC5D Chimeric Antigen Receptors and Cells Expressing the Same," offers a breakthrough in targeted cancer therapies by utilizing chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor, GPRC5D. This innovation encompasses immunoresponsive cells equipped with such CARs for effective cancer treatment. The second patent, "Vaccines Based on Mutant CALR and JAK2 and Their Uses," presents a novel approach to immunotherapy. It includes vaccines, polypeptides, and polynucleotides based on mutant CALR and JAK2 sequences, along with comprehensive methods to induce immune responses and manage clinical conditions associated with these mutations.

Career Highlights

Ricardo Attar has worked for prestigious companies in the pharmaceutical sector, including Bristol-Myers Squibb Company and Janssen Biotech, Inc. His extensive experience in these organizations has honed his expertise in drug development and innovation, making substantial advancements in therapeutic solutions for patients.

Collaborations

Throughout his career, Attar has collaborated with eminent professionals in the field. Notable coworkers include Marco Gottardis and Francois Gaudet, both of whom share a commitment to advancing cancer treatments and enhancing patient outcomes through innovative research and development.

Conclusion

Ricardo Attar's passion for innovation and his dedication to improving cancer therapies through his patents underscore his role as a trailblazer in the biomedical field. His contributions have the potential to transform therapeutic approaches, providing hope and enhanced treatment options for patients battling cancer.

Profile summary based on public USPTO records.